Iteos Therapeutics, Inc. Stock Price, News & Analysis

iTeos Therapeutics (Nasdaq: ITOS) announced a conference call scheduled for November 10, 2021, at 4:30 p.m. ET to discuss its third quarter 2021 financial results and provide a corporate update. The company specializes in developing immuno-oncology therapeutics, focusing on restoring immune responses against cancer. Their pipeline includes EOS-448, an anti-TIGIT antibody, and inupadenant, an adenosine A2A receptor antagonist, which are progressing into clinical trials. Investors can access the call by dialing provided numbers or via a live webcast.

iTeos Therapeutics, a clinical-stage biopharmaceutical company, announced participation in five virtual investor conferences throughout September 2021. Key events include the KBC Securities Life Sciences Conference on September 7 and the Wells Fargo Virtual Healthcare Conference on September 9-10. Additionally, iTeos will present at the Morgan Stanley 19th Annual Global Healthcare Conference from September 9-15, the H.C. Wainwright Annual Global Investment Conference on September 13, and the Cantor Fitzgerald Global Healthcare Conference on September 27. Audio webcasts will be accessible on their website.

iTeos Therapeutics (NASDAQ: ITOS) announced a collaboration with GSK for the co-development of EOS-448, receiving a $625 million upfront payment and potential milestone payments of $1.45 billion. The agreement includes a 40/60 cost-sharing on global development and a 50/50 profit sharing in the U.S. Initial clinical data presented shows promising anti-cancer activity for EOS-448. The company reported a cash balance of $302.9 million as of June 30, 2021, bolstered by the GSK payment, extending its runway into 2026.

iTeos Therapeutics, Inc. (Nasdaq: ITOS) will host a conference call on August 12, 2021, at 8:00 a.m. ET to report its second quarter 2021 financial results and offer a corporate update. The event will be accessible via a pre-registration link and a live audio webcast available on the company's investor relations website. iTeos is focused on immuno-oncology therapeutics with ongoing trials for EOS-448, an anti-TIGIT antibody, and inupadenant, an adenosine A2A receptor antagonist. Preliminary data indicates potential clinical activity and favorable tolerability for both candidates.

iTeos Therapeutics, Inc. (Nasdaq: ITOS) has announced the presentation of its CEO, Michel Detheux, at the Wedbush PacGrow Healthcare Conference on August 10, 2021, at 2:20 p.m. ET. The conference will feature a live webcast available on the company’s website, with an archived replay accessible for 30 days.

iTeos focuses on developing innovative immuno-oncology therapeutics, including two promising clinical-stage programs. Their lead candidate, EOS-448, targets anti-TIGIT mechanisms, showing preliminary clinical activity, while inupadenant aims to combat cancer immunosuppression.

iTeos Therapeutics (Nasdaq: ITOS), a clinical-stage biopharmaceutical firm, will have its CEO Michel Detheux, PhD, participate in a panel at the William Blair Biotech Focus Conference 2021 on July 14, 2021, at 2:10 p.m. ET. The discussion will revolve around developing therapies for new immuno-oncology targets. A live webcast of the event will be available on the company’s website, with an archived replay accessible for 30 days post-event. iTeos focuses on innovative immuno-oncology therapeutics, with clinical programs such as EOS-448 and inupadenant showing promising early results.

iTeos Therapeutics (ITOS) and GlaxoSmithKline (GSK) have announced a collaboration to co-develop EOS-448, an anti-TIGIT monoclonal antibody, currently in phase I for advanced solid tumors. Under this agreement, iTeos will receive a $625 million upfront payment, with potential milestone payments totaling up to $1.45 billion. GSK will co-commercialize EOS-448 in the US, sharing profits, while receiving exclusive commercialization rights outside the US, along with tiered royalties. The partnership aims to enhance immuno-oncology therapies targeting the CD226 axis.

iTeos Therapeutics (NASDAQ: ITOS) announced positive results from its Phase 1/2a trial of inupadenant (EOS-850), an A_2AR antagonist, at ASCO 2021. Out of 43 patients, five showed durable responses or stable disease for over six months, including noteworthy results in melanoma and non-small cell lung cancer cases. Preliminary analyses suggest that A_2AR expression correlates with clinical outcomes. The monotherapy was well-tolerated, with serious adverse events not indicating new safety concerns. iTeos plans further trials combining inupadenant with pembrolizumab and chemotherapy.

iTeos Therapeutics, a clinical-stage biopharmaceutical company, announced that CEO Michel Detheux will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 8:00 a.m. ET. A live webcast will be available on the company's website, with an archived replay for 30 days. iTeos focuses on developing innovative immuno-oncology therapeutics, including EOS-448, an anti-TIGIT antibody, and inupadenant, an adenosine A2A receptor antagonist. Both candidates are undergoing clinical trials showcasing preliminary clinical activity in adult patients with advanced solid tumors.